Hepatocellular Cancer

P1, N=66, Recruiting, Chiome Bioscience Inc. | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

P1, N=36, Terminated, M.D. Anderson Cancer Center | Trial completion date: Apr 2028 --> Jun 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2028 --> Jun 2026; < 75% participation

P2, N=58, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Jul 2027

P1, N=39, Completed, Adaptimmune | Active, not recruiting --> Completed

Mechanistic analyses showed that LINC00152 could regulate EGFR/PI3K/AKT/P21/MMP2/9 pathways in in vitro and in vivo experiments. Our results suggest that LINC00152 contributes to the oncogenic potential of hepatic cancer and that the EGFR/PI3K/AKT/P21/MMP2/9 signalling pathway might be a potential therapeutic target for hepatic cancer.

Therefore, the aberrantly expressed IL-33/ST2 axis could be a diagnostic biomarker and therapeutic target in liver diseases. In this review, we summarize the expression characteristics, mechanisms, and targeted strategies of IL-33 in hepatitis B virus (HBV) infection, acute or chronic toxic liver injury, steatohepatitis, fibrosis, cirrhosis, hepatic ischemia/reperfusion injury, and hepatocellular carcinoma.

The patient received combination chemotherapy with gemcitabine, carboplatin, and bevacizumab, achieving a near-complete metabolic response. Immunohistochemistry plays a crucial role in identifying the primary tumor origin. Management requires a staged approach with emergency surgical intervention followed by multidisciplinary oncological treatment for optimal outcomes.

In addition, virtual screening identified three potential DNASE1L3 candidates: STL167676, STK598132, and STK119225. This study developed a robust stromal senescence-associated gene signature that accurately predicts survival outcomes in HCC patients and identified candidate stromal senescence-related molecules for more effective personalized therapy.

TRIM37-triggered post-translational modification of PTEN via ubiquitination may have a vital function in promoting HCC progression. These findings suggest that targeting the TRIM37/PTEN/AKT/GSK-3β/β-Catenin axis may offer a promising therapeutic approach for the management of HCC.

This review summarizes current understanding of how T cell dysfunction, epigenetic programming, and metabolic disruption interact in chronic HCV infection. Understanding these interconnected mechanisms may guide the development of novel therapeutic strategies that combine antiviral, immunomodulatory, and metabolic interventions to achieve durable immune restoration and improved clinical outcomes.

Immunotherapy with atezolizumab (1200 mg every 3 weeks [Q3W]) combined with targeted therapy with bevacizumab (600 mg Q3W) was initiated in July 2021.A substantial temporal gap of approximately 21 months followed, after which electroacupuncture-based rehabilitation (5-Hz continuous-wave, stimulating Jiaji acupoints, Zusanli, etc) was started in May 2023. Targeted immunotherapy combined with electroacupuncture may influence neural remodeling by modulating a pro-reparative inflammatory microenvironment, which could potentially support functional reconstruction in patients with spinal metastases. However, there is no direct evidence that immunotherapy accelerates neural recovery, and these observations should be interpreted as hypothesis-generating findings requiring rigorous testing in prospective studies.

The TMEp phase integrated stereotactic body radiotherapy (SBRT), low-dose etoposide, and anlotinib, followed by CI with the programmed death 1 (PD-1)/cytotoxic T lymphocyte antigen 4 (CTLA-4) bispecific antibody cadonilimab and concurrent probiotic supplementation...The TMEp-CI-M platform may enhance the efficacy of immunotherapy in ES-SCLC, enabling durable responses even in patients with brainstem metastases. Although this platform has demonstrated promise across multiple tumor types, further prospective and mechanistic studies are warranted to confirm its clinical utility.